An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes

References

• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013 Update. http://www.idf.org/diabetesatlas. Accessed September 17, 2013
   Google Scholar
• International Diabetes Federation. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation. 2012. www.idf.org. Accessed October 1, 2013
   Google Scholar
• Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455–60
   PubMed Web of Science ®Google Scholar
• Del Prato S, Felton AM, Munro N, et al; Global Partnership for Effective Diabetes Management. Improving glucose management: ten stops to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2007;157:47–57
   Google Scholar
• Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1cheive study. Diabetes Res Clin Pract 2011;94:352–63
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009;63:522–31
   Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293–301
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–5
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58–66
   PubMed Web of Science ®Google Scholar
• McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530–9
   PubMed Web of Science ®Google Scholar
• Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393–9
   PubMed Web of Science ®Google Scholar
• Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883–8
   PubMed Web of Science ®Google Scholar
• Christiansen JS1, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003;5:446–54
   PubMed Web of Science ®Google Scholar
• Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527–32
   PubMed Web of Science ®Google Scholar
• Lee KH, Seo SJ, Smith-Palmer J, et al. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in south korea. Value in Health 2009;12(Suppl 3):S55–61
   PubMedGoogle Scholar
• Gumprecht J, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009;63:966–72
   PubMed Web of Science ®Google Scholar
• Shah S, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009;63:574–82
   PubMed Web of Science ®Google Scholar
• Shah SN, Litwak L, Haddad J, et al. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010;88(Suppl 1):S11–6
   PubMedGoogle Scholar
• Shah S, Zilov A, Malek R, et al. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011;94:364–70
   PubMed Web of Science ®Google Scholar
• Hnoosh A, Vega-Hernández G, Jugrin A, et al. PDB45 Direct medical costs of diabetes-related complications in Saudi Arabia. Value Health 2012;15:A178
   Web of Science ®Google Scholar
• Todorova L, Hnoosh A, Bloomfield E, et al. PDB20 Estimating the direct medical costs associated with diabetes-related complications in Indonesia. Value Health 2012;15:A662
   Google Scholar
• Todorova L, Hnoosh A, Korde G, et al. PDB21 Direct medical costs of diabetes-related complications in India. Value Health 2012;15:A662
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5–26
   PubMed Web of Science ®Google Scholar
• The World Bank. World Bank Open Data. USA: The World Bank. 2012. http://data.worldbank.org/. Accessed January 2, 2014
   Google Scholar
• World Health Organisation. World Health Organisation Choice Programme. http://www.who.int/choice/costs/CER_thresholds/en/index.html. Switzerland: World Health Organization. Accessed October 1, 2013
   Google Scholar
• El Naggar NK, Soewondo P, Khamseh ME, et al. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A1chieve study. Diabetes Res Clin Pract 2012;98:408–13
   PubMed Web of Science ®Google Scholar
• Soewondo P, Lindarto D, Wibisono S, et al. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A1chieve study. Diabetes Res Clin Pract 2013;100(Suppl 1):S41–6
   PubMedGoogle Scholar
• Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007;23:3209–14
   PubMed Web of Science ®Google Scholar
• Ohira M, Endo K, Oyama T, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011;60:78–85
   PubMed Web of Science ®Google Scholar
• Mäkelä JK, Schmüser C, Askonen K, et al. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland. Diabetes Res Clin Pract 2012;95:10–18
   PubMed Web of Science ®Google Scholar
• Dreyer NA, Tunis SR, Berger M, et al. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010;29:1818–25
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Pollock RF, Plun-Favreau J, et al. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Curr Med Res Opin 2010;26:1399–412
   PubMed Web of Science ®Google Scholar
• Palmer JL, Knudsen MS, Aagren M, et al. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ 2010;13:212–20
   PubMedGoogle Scholar
• Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752–74
   PubMed Web of Science ®Google Scholar